ATE553112T1 - Ttk in der diagnose und als therapeutisches target bei krebs - Google Patents
Ttk in der diagnose und als therapeutisches target bei krebsInfo
- Publication number
- ATE553112T1 ATE553112T1 AT02709637T AT02709637T ATE553112T1 AT E553112 T1 ATE553112 T1 AT E553112T1 AT 02709637 T AT02709637 T AT 02709637T AT 02709637 T AT02709637 T AT 02709637T AT E553112 T1 ATE553112 T1 AT E553112T1
- Authority
- AT
- Austria
- Prior art keywords
- ttk
- methods
- genes
- cancer
- diagnosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01037—Protein kinase (2.7.1.37)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27125401P | 2001-02-21 | 2001-02-21 | |
| PCT/US2002/005278 WO2002068444A1 (en) | 2001-02-21 | 2002-02-21 | Ttk in diagnosis and as a therapeutic target in cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE553112T1 true ATE553112T1 (de) | 2012-04-15 |
Family
ID=23034823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02709637T ATE553112T1 (de) | 2001-02-21 | 2002-02-21 | Ttk in der diagnose und als therapeutisches target bei krebs |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1377596B1 (de) |
| JP (2) | JP4429604B2 (de) |
| KR (1) | KR100876327B1 (de) |
| CN (2) | CN100578227C (de) |
| AT (1) | ATE553112T1 (de) |
| AU (1) | AU2002244112B2 (de) |
| CA (1) | CA2438092C (de) |
| NZ (1) | NZ527421A (de) |
| WO (1) | WO2002068444A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2474844A1 (en) * | 2002-02-12 | 2003-08-21 | Chiron Corporation | Cks1 inhibitors |
| TW200413725A (en) * | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| AU2003297318A1 (en) * | 2002-12-20 | 2004-07-22 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476. |
| JP4721903B2 (ja) * | 2004-01-29 | 2011-07-13 | 大日本住友製薬株式会社 | 新規腫瘍抗原蛋白質及びその利用 |
| CN102747140A (zh) * | 2004-12-08 | 2012-10-24 | 安万特药物公司 | 测量对多西他赛抗药性或敏感性的方法 |
| ES2364670T3 (es) * | 2005-02-25 | 2011-09-12 | Oncotherapy Science, Inc. | Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos ttk. |
| JP4647456B2 (ja) * | 2005-10-11 | 2011-03-09 | オンコセラピー・サイエンス株式会社 | 新規基質を用いたttk活性抑制剤のスクリーニング方法 |
| AU2006337085B2 (en) * | 2005-12-27 | 2013-12-19 | Curis, Inc. | Methods of using hedgehog kinase antagonists to inhibit hedgehog signaling and to treat hedgehog mediated disorders |
| EP2102360A2 (de) * | 2006-12-13 | 2009-09-23 | Oncotherapy Science, Inc. | Ttk als tumormarker und therapeutisches ziel für lungenkrebs |
| US8492356B2 (en) | 2007-12-21 | 2013-07-23 | University Health Network | Methods of inhibiting tumor growth using TTK antagonists |
| WO2010007756A1 (ja) * | 2008-07-14 | 2010-01-21 | 塩野義製薬株式会社 | Ttk阻害作用を有するピリジン誘導体 |
| TW201102081A (en) | 2009-05-11 | 2011-01-16 | Oncotherapy Science Inc | TTK peptides and vaccines including the same |
| TW201107329A (en) | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
| CA2822491C (en) * | 2011-01-21 | 2023-02-14 | Basilea Pharmaceutica Ag | Bubr1 as a biomarker for furazanobenzimidazoles |
| PL3484888T3 (pl) | 2016-07-18 | 2023-06-26 | University Health Network | Stałe postacie inhibitora TTK |
| CN117065023B (zh) * | 2023-06-16 | 2025-11-21 | 华中科技大学同济医学院附属协和医院 | Ttk基因及ttk抑制剂在治疗血管损伤后再狭窄中的功能及应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6586581B1 (en) * | 1999-03-23 | 2003-07-01 | The Mt. Sinai School Of Medicine Of New York University | Prolactin regulatory element binding protein and uses thereof |
| AU1339701A (en) * | 1999-10-22 | 2001-05-08 | Lifespan Biosciences, Inc. | Anti-cancer nucleic acid and protein targets |
-
2002
- 2002-02-21 KR KR1020037010968A patent/KR100876327B1/ko not_active Expired - Fee Related
- 2002-02-21 CA CA2438092A patent/CA2438092C/en not_active Expired - Fee Related
- 2002-02-21 CN CN02805272A patent/CN100578227C/zh not_active Expired - Fee Related
- 2002-02-21 NZ NZ527421A patent/NZ527421A/en unknown
- 2002-02-21 CN CN200910253120A patent/CN101732717A/zh active Pending
- 2002-02-21 AT AT02709637T patent/ATE553112T1/de active
- 2002-02-21 JP JP2002567954A patent/JP4429604B2/ja not_active Expired - Fee Related
- 2002-02-21 EP EP02709637A patent/EP1377596B1/de not_active Expired - Lifetime
- 2002-02-21 WO PCT/US2002/005278 patent/WO2002068444A1/en not_active Ceased
- 2002-02-21 AU AU2002244112A patent/AU2002244112B2/en not_active Ceased
-
2008
- 2008-10-27 JP JP2008276182A patent/JP4838835B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002244112B2 (en) | 2007-05-10 |
| NZ527421A (en) | 2005-05-27 |
| EP1377596B1 (de) | 2012-04-11 |
| WO2002068444A1 (en) | 2002-09-06 |
| JP2004526716A (ja) | 2004-09-02 |
| CA2438092C (en) | 2011-08-09 |
| EP1377596A4 (de) | 2005-07-13 |
| KR100876327B1 (ko) | 2008-12-31 |
| CN101732717A (zh) | 2010-06-16 |
| JP4838835B2 (ja) | 2011-12-14 |
| JP4429604B2 (ja) | 2010-03-10 |
| EP1377596A1 (de) | 2004-01-07 |
| JP2009143890A (ja) | 2009-07-02 |
| CN1492875A (zh) | 2004-04-28 |
| KR20030076695A (ko) | 2003-09-26 |
| CN100578227C (zh) | 2010-01-06 |
| CA2438092A1 (en) | 2002-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE553112T1 (de) | Ttk in der diagnose und als therapeutisches target bei krebs | |
| Pirsaheb et al. | Current advances of carbon dots based biosensors for tumor marker detection, cancer cells analysis and bioimaging | |
| Verdoes et al. | Improved quenched fluorescent probe for imaging of cysteine cathepsin activity | |
| EP4282405A3 (de) | Nachweis von krebs-biomarkern mittels nanopartikeln | |
| MX2009010439A (es) | Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama. | |
| ATE454468T1 (de) | Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose | |
| MX2018011725A (es) | Metodo para emplear expresion genica para determinar pronostico de cancer de prostata. | |
| ATE229073T1 (de) | Protein e25a, methoden zu dessen herstellung und anwendung | |
| WO2004106495A3 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer | |
| DE602006015966D1 (de) | Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie | |
| WO2003070979A3 (en) | Materials and methods relating to cancer diagnosis | |
| WO2023004079A3 (en) | Compositions and methods for detection of liver cancer | |
| WO2017217807A3 (ko) | Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물 | |
| BRPI0412110A (pt) | genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos | |
| ATE545867T1 (de) | I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom | |
| WO2003083102A3 (en) | Cancer associated protein phosphatases and their uses | |
| CY1115258T1 (el) | Μεθοδοι και χρησεις που περιλαμβανουν τις γενετικες παρεκκλισεις του ναv3 και την παρεκκλινουσα εκφραση πολλαπλων γονιδιων | |
| Que et al. | New strategy for antimetastatic treatment of lung cancer: a hypothesis based on circulating tumour cells | |
| Ma et al. | Pan-cancer analysis of ADAMs: A promising biomarker for prognosis and response to chemotherapy and immunotherapy | |
| WO2009019366A3 (fr) | Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal | |
| BRPI0608429A2 (pt) | método e kit para prognóstico ou avaliação da eficácia do tratamento de um tumor sólido em um paciente de interesse; e método para a identificação de marcadores que sejam prognósticos de um tumor sólido | |
| WO2006065940A3 (en) | Identification and use of prognostic and predictive markers in cancer treatment | |
| WO2003076651A3 (en) | Cancer associated araf1 protein kinase and its uses | |
| Kundranda et al. | Role of ctDNA in the Management of Gallbladder Cancer | |
| Cherciu et al. | Targeted Confocal Laser Endomicroscopy (CLE) for the Assessment of Putative Cancer Stem Cell Markers in Colorectal cancer-A Pilot Study |